BRVE.US Braveheart Bio, Inc. Common Stock

Healthcare Biotechnology USA Stocks
19.62 USD
Close of Nov 14, 2026
16.70 32.00
Market cap
USD 1.77B
P/E
-
P/B
3.71x
ROE
-14.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BRVE.US undervalued?

Graham number

The Graham number of Braveheart Bio, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Braveheart Bio, Inc. Common Stock fundamental analysis

No fundamental analysis for Braveheart Bio, Inc. Common Stock yet.

Braveheart Bio, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Braveheart Bio, Inc. Common Stock

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Full company profile